Jpmorgan Chase & CO Pacira Bio Sciences, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 652,476 shares of PCRX stock, worth $14.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

652,476

Previous 756,176 13.71%

Holding current value

$14.8 Million

Previous $14.2 Million 13.81%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$18.33 - $27.25 $1.9 Million - $2.83 Million	-103,700 Reduced 13.71%	652,476 $16.2 Million
Q4 2024 Feb 12, 2025	BUY	$15.3 - $20.33 $309,090 - $410,706	20,202 Added 2.74%	756,176 $14.2 Million
Q3 2024 Dec 26, 2024	BUY	$11.7 - $28.46 $1.58 Million - $3.85 Million	135,363 Added 22.54%	735,974 $11.1 Million
Q3 2024 Nov 08, 2024	BUY	$11.7 - $28.46 $1.58 Million - $3.85 Million	135,363 Added 22.54%	735,974 $11.1 Million
Q2 2024 Dec 26, 2024	SELL	$25.5 - $31.51 $3.45 Million - $4.27 Million	-135,363 Reduced 18.39%	600,611 $17.2 Million
Q2 2024 Aug 12, 2024	BUY	$25.5 - $31.51 $13.1 Million - $16.2 Million	515,539 Added 606.0%	600,611 $17.2 Million
Q1 2024 Dec 26, 2024	SELL	$27.7 - $35.48 $18 Million - $23.1 Million	-650,902 Reduced 88.44%	85,072 $2.49 Million
Q1 2024 May 10, 2024	SELL	$27.7 - $35.48 $1.54 Million - $1.97 Million	-55,578 Reduced 39.52%	85,072 $2.49 Million
Q4 2023 Dec 26, 2024	SELL	$26.32 - $34.31 $15.7 Million - $20.4 Million	-595,324 Reduced 80.89%	140,650 $4.75 Million
Q4 2023 Feb 12, 2024	BUY	$26.32 - $34.31 $1.31 Million - $1.71 Million	49,812 Added 54.84%	140,650 $4.75 Million
Q3 2023 Nov 14, 2023	SELL	$30.68 - $40.09 $1.18 Million - $1.55 Million	-38,592 Reduced 29.82%	90,838 $2.79 Million
Q2 2023 Aug 11, 2023	BUY	$36.12 - $47.5 $1.64 Million - $2.16 Million	45,533 Added 54.27%	129,430 $5.19 Million
Q1 2023 May 18, 2023	BUY	$35.53 - $43.38 $2.13 Million - $2.61 Million	60,067 Added 252.06%	83,897 $3.42 Million
Q1 2023 May 11, 2023	SELL	$35.53 - $43.38 $1.98 Million - $2.42 Million	-55,814 Reduced 70.08%	23,830 $972,000
Q4 2022 Feb 13, 2023	BUY	$38.19 - $57.45 $7,790 - $11,719	204 Added 0.26%	79,644 $3.07 Million
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $462,902 - $532,012	9,034 Added 12.83%	79,440 $4.23 Million
Q2 2022 Aug 11, 2022	BUY	$51.49 - $81.64 $490,081 - $777,049	9,518 Added 15.63%	70,406 $4.1 Million
Q1 2022 May 11, 2022	BUY	$60.03 - $76.49 $561,280 - $715,181	9,350 Added 18.14%	60,888 $4.65 Million
Q4 2021 Feb 10, 2022	BUY	$47.97 - $62.21 $27,342 - $35,459	570 Added 1.12%	51,538 $3.1 Million
Q3 2021 Nov 12, 2021	BUY	$54.64 - $61.3 $2.78 Million - $3.12 Million	50,968 New	50,968 $2.86 Million

Others Institutions Holding PCRX

# of Institutions

259

Shares Held

51.2M

Call Options Held

289K

Put Options Held

130K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.04B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Pacira Bio Sciences, Inc. Transaction History